Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
about
Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South AfricaDiagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?Advances and hurdles on the way toward a leprosy vaccine.Tuberculosis Biomarkers: From Diagnosis to ProtectionDecay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis casesCorrelation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden settingIs IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study.New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response.Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006-2008). Evaluation of QuantiFERON-TB gold in tube for TB diagnosisReversion of the ELISPOT test after treatment in Gambian tuberculosis cases.Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study.Temporal dynamics of interferon gamma responses in children evaluated for tuberculosisThe impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosisLymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.T-SPOT.TB responses during treatment of pulmonary tuberculosis.In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection.T-cell-based diagnosis of tuberculosis infection in children in Lithuania: a country of high incidence despite a high coverage with bacille Calmette-Guerin vaccinationReversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected childrenTuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay.Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controlsSerial interferon-gamma release assays during treatment of active tuberculosis in young adults.Assessment of Imprecision in gamma interferon release assays for the detection of exposure to Mycobacterium tuberculosisThe immunology of tuberculosis: from bench to bedside.Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapyInterferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay.Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatmentPairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United StatesProspective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individualsImmunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in TanzaniaKinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with tuberculous meningitis.Risk factors for latent tuberculosis infection in close contacts of active tuberculosis patients in South Korea: a prospective cohort study.Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary reportLatent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test.The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assay.
P2860
Q21261534-4147C26F-CFC1-4C20-88AD-709A7BBE7D9BQ22241488-7CE3E5AB-A4D3-40E7-9E91-285893A09C03Q22305432-384244AA-1F92-40E9-8B73-B2ACCB91B401Q26741141-52480DB9-3D7F-4A18-9BDD-9839EA00EA7FQ28475371-5D1AE0A7-C406-4FF5-B854-5EE1F833B9E9Q28729742-335DEC32-0F74-4635-AEF8-A188BD1CB6AEQ28749413-C431F13F-1CFF-4A0E-807C-E016763A2ADBQ30840526-C73FC8B8-9411-4268-92D7-6AF7EDB9A4D2Q30907264-76FE5185-FE3B-4B78-9910-2A6EB0697626Q30979334-30B7B052-3F78-412C-B528-0CCB5374EA34Q31139426-1FF5CB26-A3C8-4206-8814-CCA1F186BDBBQ33238061-C2CD6112-8A03-49C8-BB4D-F9AC365318A7Q33377055-F3469B78-DE21-459B-AC1D-A9BA733D45E0Q33397721-773C70FF-B6F2-4D72-837A-88190B789E0FQ33401266-D0E8438A-439E-447A-B358-ECC1B1976C4DQ33411543-9CFC4923-D361-4300-B0DD-F1DE9BA1D834Q33413454-7E939DB5-A277-465D-B113-3C981747C8D4Q33429956-878FB4F6-2C46-4165-B4B2-8CA82A32D4A7Q33444815-14252834-C56E-4F51-A0A3-D275CCDD0590Q33494752-3FD89CAE-8B84-46CF-9177-2ACD27A073D6Q33589272-AB7A3191-E26C-46E3-86C5-C27AA3A866BCQ33591688-09866447-6DAC-43E2-83B8-FA495D2BFD00Q33614310-FEA6740E-BBC5-4772-8F9E-177D3790031AQ33694852-39868DF9-ED9D-42C0-B079-4740ACB75482Q33719971-944DEA4D-B935-470B-823E-58117A8653F1Q33768656-0AD89744-8A92-4F89-B8E0-F6E945595B07Q33777367-F99FE192-6B49-4F7E-ADB1-418713D063F9Q33807147-5DD49018-238B-4912-9EC0-ED673577EC34Q33905874-BBC5407B-17E0-49DB-A798-590A02C2355AQ34137874-EBFB4743-1B90-45A6-A4A3-6B4638F7B3CBQ34143564-5585AA99-B907-4DC0-BF82-FE333F2F9518Q34185319-D3BB5262-E3C7-443D-AB07-A933F90AFA8BQ34218697-E3DE9498-4302-49D6-A2FE-2BDE510DA60BQ34299551-E69BE5EA-9817-4D15-AC6C-C8EF4659EA42Q34312118-CF3FBE54-9849-4EFE-A442-92026F6A88AEQ34451405-515DCAF8-E523-48B3-998B-9BFB1031A408Q34544215-9E2629DB-43FB-4669-8DDE-8486DE106C88Q34691255-B6B7A0C7-17A2-4743-9513-DF7E9F4EF330Q34872252-43E221F8-F287-4393-A110-2E8A82B045C6Q35036937-3CB90602-F54C-44B7-9065-BF065C48B02F
P2860
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@en
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@nl
type
label
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@en
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@nl
prefLabel
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@en
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@nl
P50
P356
P1476
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.
@en
P2093
Donatella Vincenti
Stefania Carrara
P304
P356
10.1086/381754
P407
P577
2004-02-17T00:00:00Z